Koca Timur, Gocen Vardar Nurcihan, Aksoy Rahmi Atıl, Korcum Aylin Fidan
Department of Radiation Oncology, Akdeniz University, 07070 Antalya, Turkey.
Department of Radiation Oncology, Izmir City Hospital, 35540 Izmir, Turkey.
Curr Oncol. 2025 Jan 13;32(1):39. doi: 10.3390/curroncol32010039.
: Inflammatory biomarkers have been shown to possess both prognostic and predictive significance in various cancers. Among the emerging biomarkers, the pan-immune-inflammation value (PIV) has recently been introduced as a novel indicator representing both the immune response and the systemic inflammatory state. This study aims to comprehensively evaluate the predictive value of inflammatory biomarkers on survival outcomes in cervical cancer patients undergoing chemoradiotherapy. : A total of 90 patients who had undergone chemoradiotherapy for cervical cancer were included. Data on demographics, treatment protocols, pre-treatment blood parameters, and survival outcomes were collected. The association between inflammatory biomarkers and survival outcomes was investigated through univariate and multivariate analyses. The univariate analysis identified the following as predictors of progression-free survival (PFS): neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), PIV, C-reactive protein (CRP), albumin, and tumor size. Multivariate analysis revealed that only the PIV significantly predicted PFS (HR 3.05, 95% CI 1.0 to 9.3, = 0.04). In the univariate analysis, several variables were predictive of overall survival (OS), including NLR, PLR, MLR, SII, PIV, CRP, LDH, albumin, tumor size, and Eastern Cooperative Oncology Group Performance Status (ECOG PS). Multivariate analysis revealed CRP (HR 3.41, 95% CI 1.5 to 7.7, = 0.003) and ECOG PS (HR 4.78, 95% CI 1.3 to 17.3, = 0.01) predictive of OS, with PIV approaching statistical significance (HR 2.56, 95% CI 0.8 to 7.6, = 0.09). : This study provides the first comprehensive analysis of the association between cervical cancer and various inflammatory biomarkers. Many of these biomarkers have demonstrated predictive value for survival outcomes in patients with cervical cancer undergoing definitive chemoradiotherapy. Among the biomarkers evaluated, CRP and PIV were identified as the most predictive, warranting further exploration in future research.
炎症生物标志物已被证明在各种癌症中具有预后和预测意义。在新兴的生物标志物中，全免疫炎症值（PIV）最近被引入作为一种代表免疫反应和全身炎症状态的新型指标。本研究旨在全面评估炎症生物标志物对接受放化疗的宫颈癌患者生存结局的预测价值。
共纳入90例接受宫颈癌放化疗的患者。收集了人口统计学、治疗方案、治疗前血液参数和生存结局的数据。通过单因素和多因素分析研究炎症生物标志物与生存结局之间的关联。单因素分析确定以下因素为无进展生存期（PFS）的预测因素：中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、单核细胞与淋巴细胞比值（MLR）、全身免疫炎症指数（SII）、PIV、C反应蛋白（CRP）、白蛋白和肿瘤大小。多因素分析显示，只有PIV显著预测PFS（风险比[HR]3.05，95%置信区间[CI]1.0至9.3，P = 0.04）。在单因素分析中，几个变量可预测总生存期（OS），包括NLR、PLR、MLR、SII、PIV、CRP、乳酸脱氢酶（LDH）、白蛋白、肿瘤大小和东部肿瘤协作组体能状态（ECOG PS）。多因素分析显示CRP（HR 3.41，95%CI 1.5至7.7，P = 0.003）和ECOG PS（HR 4.78，95%CI 1.3至17.3，P = 0.01）可预测OS，PIV接近统计学显著性（HR 2.56，95%CI 0.8至7.6，P = 0.09）。
本研究首次全面分析了宫颈癌与各种炎症生物标志物之间的关联。这些生物标志物中的许多已证明对接受根治性放化疗的宫颈癌患者的生存结局具有预测价值。在所评估的生物标志物中，CRP和PIV被确定为最具预测性的，值得在未来研究中进一步探索。
